New Concepts and Therapies of Hypertrophic Cardiomyopathy

and non-dihydropyridine calcium channel blockers, which reduce myocardial energy demand.Other alternatives have been used, such as perhexiline, trimetazidine, and ranolazine which affect myocardial energy metabolism at different levels or inhibit the production of aldosterone [3].In patients with persistent symptoms of LVOTO, invasive treatments include surgical myectomy, alcohol septal ablation, or right ventricular pacing.Recent cardio selective drugs have shown promising results in reducing obstruction and improving function, such as mavacamten, which inhibits myosin binding to actin [4].The main modifiable cardiovascular risk factors can be reduced and prevented through physical conditioning, improving functional capacity, and reducing morbidity and mortality.Studies show that physical conditioning can benefit HCM patients and be safe, good